Janux Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
JANX$12.76-27.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and par value data)
| March 31,2024 | December 31,2023 | |
|---|---|---|
| Assets · (unaudited) | ||
| Current assets: | ||
| Cash and cash equivalents | $212,803 | $19,205 |
| Accounts receivable | 519 | — |
| Short-term investments | 438,960 | 324,823 |
| Prepaid expenses and other current assets | 6,384 | 5,213 |
| Total current assets | 658,666 | 349,241 |
| Restricted cash | 816 | 816 |
| Property and equipment, net | 6,517 | 7,003 |
| Operating lease right-of-use assets | 20,461 | 20,838 |
| Other long-term assets | 2,524 | 2,509 |
| Total assets | $688,984 | $380,407 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $2,254 | $2,424 |
| Accrued expenses | 5,810 | 7,387 |
| Current portion of deferred revenue | 972 | 1,705 |
| Current portion of operating lease liabilities | 1,573 | 1,517 |
| Total current liabilities | 10,609 | 13,033 |
| Operating lease liabilities, net of current portion | 22,612 | 23,025 |
| Total liabilities | 33,221 | 36,058 |
| Commitments and contingencies (Note 3) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; authorized shares – 10,000,000 at March 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding at March 31, 2024 and December 31, 2023 | — | — |
| Common stock, $0.001 par value; authorized shares – 200,000,000 at March 31, 2024 and December 31, 2023, respectively; issued shares – 51,846,342 and 46,262,759 at March 31, 2024 and December 31, 2023, respectively; outstanding shares – 51,840,571 and 46,252,440 at March 31, 2024 and December 31, 2023, respectively | 51 | 46 |
| Additional paid-in capital | 839,759 | 512,401 |
| Accumulated other comprehensive income (loss) | (524) | 665 |
| Accumulated deficit | (183,523) | (168,763) |
| Total stockholders’ equity | 655,763 | 344,349 |
| Total liabilities and stockholders’ equity | $688,984 | $380,407 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.